In this video, we explore the findings from the groundbreaking EORTC-1203 GITC "INNOVATION" study presented at the 2025 ASCO Gastrointestinal Cancers Symposium ASCO GI 2025
Study Overview:
Title: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer
First Author: Anna Wagner, Lausanne University Hospital and University of Lausanne
Abstract Number: LBA331
Trial Registration: NCT02205047
What You'll Learn:
Background: Discover why 10-20% of gastric cancers (GC) are HER-2 positive and the undefined role of perioperative anti-HER2 treatment.
Methods: Understand the design of this randomized, open-label phase II trial involving 172 patients with HER-2 positive gastric or esophagogastric junction cancer. Patients were randomized into three arms:
Arm A: Chemotherapy (CT) alone
Arm B: CT plus Trastuzumab (T)
Arm C: CT plus Trastuzumab and Pertuzumab (P)
Results:
Detailed analysis of progression-free survival (PFS) and overall survival (OS) with significant findings on how treatment amendments affected outcomes.
Statistical insights including hazard ratios and survival rates at 3 and 5 years for each treatment arm.
Conclusions: Discussion on the observed trends, particularly the non-significant advantages of adding T to CT and the potentially detrimental effect of adding P.
Key Takeaways:
The study highlights the complexities in using major pathological response rates as a surrogate for survival in gastric cancer treatment.
Implications for future research and practice in the field of oncology, especially regarding the integration of targeted therapies in perioperative settings.
Join the Discussion:
Share your thoughts or questions about the study in the comments below!
Don't forget to like, share, and subscribe for more updates on clinical oncology research. Hit the bell icon to get notified about our latest videos.
Timestamps:
0:00 - Introduction to the trial background and the known benefits of trastuzumab.
0:16 - Discussion on the rationale for including trastuzumab in curative settings.
0:32 - Explanation of the design of the "Innovation" trial.
0:44 - Description of the trial's three treatment arms.
0:56 - Change in chemotherapy regimen post-FLOT-4 trial publication.
1:17 - Continuation of antibody treatment post-chemotherapy.
1:42 - Presentation of trial results showing improvement in major pathologic response rate.
2:34 - Highlighting the significant GI toxicity with the double antibody combination.
3:19 - Benefits observed in patients with major pathologic response.
4:04 - Conclusion on the clinical meaningfulness of adding trastuzumab to chemotherapy for HER2-positive gastric cancer treatment.
Disclosures:
The study was funded by an educational grant from Roche to EORTC.
Tags:
#GastricCancer #HER2Positive #OncologyResearch #Trastuzumab #Pertuzumab #ClinicalTrial #ASCO2025 #CancerTreatment #MedicalResearch #SurvivalRates
Disclaimer: This video provides an overview of the study for educational purposes and should not be considered medical advice. Always consult with a healthcare provider for medical advice.
Thank you for watching, and let's advance cancer care together!